徐延勇

  • 职称:青年研究员

  • 电子邮箱:yanyong_xu@fudan.edu.cn

  • 办公地点:科研二号楼A座

  • 教育经历

  • 工作经历

  • 研究方向

  • 科研项目

  • 学术兼职

  • 代表性论著

  • 2012-2015    武汉大学   生物化学与分子生物学专业   博士

  • 2008-2011    天津医科大学   生物医学工程专业       硕士

  • 2004-2008    山东省第一医科大学 生命科学学院       学士

  • 2021-至今     复旦大学基础医学院   青年研究员

  • 2019-2021     Northeast Ohio Medical University   研究助理教授

  • 2016-2018     Northeast Ohio Medical University   博士后

  • 肝脏糖脂代谢紊乱与代谢性疾病调控

  • 脂蛋白代谢与动脉粥样硬化

  • 2022-2026,国家自然科学基金委面上项目

  • 2024-2028,国家自然科学基金委面上项目

  • JBC编委

  • 中国生物化学与分子生物学代谢专业分会委员

  • 中国生物化学与分子生物学脂质与脂蛋白专业委员会委员

  • 中国病理与生理学内分泌与代谢专业委员会委员

  • Guangze Shao, Jitu Xu, Chencheng Hu, Wenyao Jia, Xitong Xu, Yue Gu, Luming Zhang, Zhihuang Zheng , Jiayan Zhong, Siqi Zhu, Shenghao Meng, Zhonghua Zhao, Zhigang Zhang, Jun Liu*, Yanyong Xu* and Huijuan Wu*. Podocyte YAP ablation decreases podocyte adhesion and exacerbates FSGS progression through α3β1 integrin. J Pathol. 2025 Jan;265(1):84-98. doi: 10.1002/path.6370.

  • Xuguang Yang , Bo Deng , Weiwei Zhao, Yangyang Guo, Yaqi Wan , Zhihao Wu , Sheng Su, Jingyan Gu, Xiaoqian Hu, Wenxue Feng, Chencheng Hu, Jia Li, Yanyong Xu*, Xiaowu Huang*, Yuli Lin* FABP5+ lipid-loaded macrophages process tumor-derived unsaturated fatty acid signal to suppress T-cell antitumor immunity. J Hepatol.  2024 Sep 30:S01688278(24)02569-8.doi: 10.1016/j.jhep.2024.09.029.

  • Shuwei Hu# *, Rui Li #, Dongxu Gong #, Pei Hu #, Jitu Xu , Yingjie Ai, Xiaojie Zhao, Chencheng Hu, Minghuan Xu, Chenxi Liu, Shuyu Chen, Jie Fan, Zhonghua Zhao, Zhigang Zhang, Huijuan Wu*, and Yanyong Xu*. Atf3-mediated metabolic reprogramming in hepatic macrophage orchestrates metabolic dysfunction-associated steatohepatitis. Science Advances. 2024 Jul 26;10(30):eado3141. doi: 10.1126/sciadv.ado3141. Epub 2024 Jul 24.

  • Shuwei Hu# , Yingdong Zhu# , Xiaojie Zhao# , Rui Li, Guangze Shao, Dongxu Gong, Chencheng Hu, Hongjun Liu, Kexin Xu, Chenxi Liu, Minghuan Xu, Zhonghua Zhao, Tao Li, Zhigang Hu, Mengle Shao, Jun Liu, Xinwei Li, Huijuan Wu, Jing Li*, and Yanyong Xu*. Hepatocytic Lipocalin-2 Regulates HDL Metabolism and Atherosclerosis via Nedd4-1-SR-BI Axis.Developmental Cell. 2023 Nov 6;58(21):2326-2337.e5. doi: 10.1016/j.devcel.2023.09.007. Epub 2023 Oct 19.

  • Zhiyuan Fang#, Yanyong Xu#, Guowen Liu#, Qi Shao, Xiaodi Niu, Wenjun Tai, Taiyu Shen, Minghe Fan, Meng Chen, Lin Lei, Wenwen Gao, Yuxiang Song, Zhe Wang, Xiliang Du, Xinwei Li. Narirutin activates TFEB (transcription factor EB) to protect against acetaminophen-induced liver injury by targeting PPP3/calcineurin. Autophagy,2023 Feb 13. doi: 10.1080/15548627.2023.2179781.

  • Yanyong Xu#*, Shuwei Hu#, Kavita Jadhav, Yingdong Zhu, Xiaoli Pan, Liya Yin, Yanqiao Zhang*. Hepatocytic Activating Transcription Factor 3 Protects Against Steatohepatitis Via Hepatocyte Nuclear Factor 4α. Diabetes, 2021 Nov;70:2506-25172021.

  • Yanyong Xu #, Yuanyuan Li #, Kavita Jadhav #,   Xiaoli Pan, Yingdong Zhu, Shuwei Hu, Shaoru Chen, Liuying Chen, Yong Tang, Ling Yang, David Q.-H. Wang, Liya Yin, Yanqiao Zhang*.  Hepatocyte ATF3 protects against atherosclerosis by regulating HDL and bile acid metabolism. Nature Metabolism, 2021; 3:59-74.

  • Yanyong Xu #, Yingdong Zhu, Shuwei Hu, Yang Xu, Diane Stroup, Xiaoli Pan, Fathima Cassim Bawa, Shaoru Chen, Raja Gopoju, Liya Yin, and Yanqiao Zhang*. Hepatocyte Nuclear Factor 4α prevents the steatosis-to-NASH progression by regulating the P53 and bile acid signaling. Hepatology, 2021 ;73(6):2251-2265.

  • Yanyong Xu #, Yang Xu #, Yingdong Zhu#, Huihui Sun, Cody Juguilon, Feng Li, Daping Fan, Liya Yin, and Yanqiao Zhang*. Macrophage MiR-34a Is A Key Regulator of Cholesterol Efflux and Atherosclerosis. Molecular Therapy, 2020 ;28:202-216.

  • Yanyong Xu#, Yingdong Zhu#, Shuwei Hu, Xiaoli Pan, Liya Yin, and Yanqiao Zhang*. Hepatocyte miR-34a is a key regulator of the development and progression of non-alcoholic fatty liver disease. Molecular Metabolism, 2021 Sep;51:101244. doi: 10.1016/j.molmet.2021.101244.